Isao Teshirogi, Shionogi CEO (Kiyoshi Ota/Bloomberg via Getty Images)

Sh­iono­gi backs F2G in de­vel­op­ing rare-dis­ease an­ti­fun­gal in Eu­rope and Asia

Sh­iono­gi, an ac­tive play­er in the arid field of an­timi­cro­bials, has now set its eye on the ad­ja­cent sphere of an­ti­fun­gals.

The Japan-based phar­ma is part­ner­ing with F2G, which de­scribes it­self as a “rare fun­gal dis­ease com­pa­ny,” to push F2G’s olo­rofim through clin­i­cal tri­als and reg­u­la­to­ry ac­tion in Eu­rope and Asia, the two com­pa­nies an­nounced to­day. Olo­rofim is be­ing test­ed to treat in­va­sive as­pergillo­sis, a rare mold in­fec­tion that can im­pact im­muno­sup­pressed peo­ple, specif­i­cal­ly those that have re­ceived cer­tain can­cer ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.